IP Library › Granted Patent US 6,972,185
Granted Patent B2
US 6,972,185 · App. 09/989,735 · Granted Dec 6, 2005

Nucleic acids encoding PRO844 polypeptides

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,972,185
App. No.
09/989,735
Granted
Dec 6, 2005
Kind
B2
Abstract

The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.

Claims (51)

1. An isolated nucleic acid having at least 80% nucleic acid sequence identity to:

(a) a nucleic acid sequence encoding the polypeptide of SEQ ID NO:345;

(b) a nucleic acid sequence encoding the polypeptide of SEQ ID NO:345, lacking its associated signal peptide;

(c) the nucleic acid sequence of SEQ ID NO:344;

(d) the full-length coding sequence of the nucleic acid sequence of SEQ ID NO:344; or

(e) the full-length coding sequence of the cDNA deposited under ATCC accession number 209976;

wherein the polypeptide encoded by said nucleic acid induces chondrocyte proliferation.

2. An isolated nucleic acid of claim 1 having at least 85% nucleic acid identity to:

(a) a nucleic acid sequence encoding the polypeptide of SEQ ID NO:345;

(b) a nucleic acid sequence encoding the polypeptide of SEQ ID NO:345, lacking its associated signal peptide;

(c) the nucleic acid sequence of SEQ ID NO:344;

(d) the full-length coding sequence of the nucleic acid sequence of SEQ ID NO:344; or

(e) the full-length coding sequence of the cDNA deposited under ATCC accession number 209976;

wherein the polypeptide encoded by said nucleic acid induces chondrocyte proliferation.

3. An isolated nucleic acid of claim 1 having at least 90% nucleic acid sequence identity to:

(a) a nucleic acid sequence encoding the polypeptide of SEQ ID NO:345;

(b) a nucleic acid sequence encoding the polypeptide of SEQ ID NO:345, lacking its associated signal peptide;

(c) the nucleic acid sequence of SEQ ID NO:344;

(d) the full-length coding sequence of the nucleic acid sequence of SEQ ID NO:344; or

(e) the full-length coding sequence of the cDNA deposited under ATCC accession number 209976;

wherein the polypeptide encoded by said nucleic acid induces chondrocyte proliferation.

4. An isolated nucleic acid of claim 1 having at least 95% nucleic acid sequence identity to:

(a) a nucleic acid sequence encoding the polypeptide of SEQ ID NO:345;

(b) a nucleic acid sequence encoding the polypeptide of SEQ ID NO:345, lacking its associated signal peptide;

(c) the nucleic acid sequence of SEQ ID NO:344;

(d) the full-length coding sequence of the nucleic acid sequence of SEQ ID NO:344; or

(e) the full-length coding sequence of the cDNA deposited under ATCC accession number 209976;

wherein the polypeptide encoded by said nucleic acid induces chondrocyte proliferation.

5. An isolated nucleic acid of claim 1 , having at least 99% nucleic acid sequence identity to:

(a) a nucleic acid sequence encoding the polypeptide of SEQ ID NO: 345 ;

(b) a nucleic acid sequence encoding the polypeptide of SEQ ID NO: 345 , lacking its associated signal peptide;

(c) the nucleic acid sequence of SEQ ID NO:344;

(d) the full-length coding sequence of the nucleic acid sequence of SEQ ID NO:344; or

(e) the full-length coding sequence of the cDNA deposited under ATCC accession number 209976;

wherein the polypeptide encoded by said nucleic acid induces chondrocyte proliferation.

6. An isolated nucleic acid comprising:

(a) a nucleic acid sequence encoding the polypeptide of SEQ ID NO:345;

(b) a nucleic acid sequence encoding the polypeptide of SEQ ID NO:345, lacking its associated signal peptide;

(c) the nucleic acid sequence of SEQ ID NO:344;

(d) the full-length coding sequence of the nucleic acid sequence of SEQ ID NO:344; or

(e) the full-length coding sequence of the cDNA deposited under ATCC accession number 209976;

wherein the polypeptide encoded by said nucleic acid induces chondrocyte proliferation.

7. The isolated nucleic acid of claim 6 , comprising a nucleic acid sequence encoding the polypeptide of SEQ ID NO:345.

8. The isolated nucleic acid of claim 6 , comprising a nucleic acid sequence encoding the polypeptide of SEQ ID NO:345, lacking is associated signal peptide.

9. The isolated nucleic acid of claim 6 comprising the nucleic acid sequence of SEQ ID NO:344.

10. The isolated nucleic acid of claim 6 comprising the full-length coding sequence of the nucleic acid sequence of SEQ ID NO:344.

11. The isolated nucleic acid of claim 6 comprising the full-length coding sequence of the cDNA deposited under ATCC accession number 209976.

12. A vector comprising the nucleic acid of claim 6 .

13. The vector of claim 12 , wherein said nucleic acid is operably linked to control sequences recognized by a host cell transformed with the vector.

14. An isolated cell comprising the vector of claim 12 .

15. The host cell of claim 14 , wherein said cell is a CHO cell, an E. coli or a yeast cell.